Getting medicines to those who need them most

We recognize that the patients and families who battle life-threatening diseases anxiously await more effective medicines with each passing day. Knowing this drives us to work harder, to deliver transformative treatments more swiftly.

We also seek to ensure any medicine we develop is safe and effective and follows the rigorous guidelines established by regulatory agencies.

We strive to balance these two complementary and vital goals in all that we do.

To learn more about our clinical trials, visit blueprintclinicaltrials.com or contact us in the U.S. at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768), and in Europe at medinfoeurope@blueprintmedicines.com or +31 85 064 4001.

Our clinical trials

Our clinical trials in

Systemic mastocytosis (SM)

Trial Phase

Trial Phase 2

Target Population

Target Population

Aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia

Study Status

Study Status

Active, fully enrolled

ClinicalTrials.gov
Study Number

Study Number

NCT03580655

Trial Phase

Trial Phase 2

Target Population

Target Population

Indolent SM

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03731260

Trial Phase

BP_Web_3.0_Trial_2-3

Target Population

Target Population

Indolent SM

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04910685

Our clinical trials in

RET-altered cancers

Trial Phase

Trial Phase 1/2

Target Population

Target Population

RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or other solid tumors with a RET fusion or mutation

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03037385

Trial Phase

Trial Phase 3

Target Population

Target Population

First-line RET fusion-positive, metastatic NSCLC

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04222972

Trial Phase

Trial Phase 3

Target Population

Target Population

Patients with locally advanced or metastatic RET-mutated MTC who have not previously received a standard of care multi-kinase inhibitor therapy

Study Status

Not yet recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04760288

Our clinical trials in

Hepatocellular carcinoma (HCC)

Trial Phase

Trial Phase 1b/2

Target Population

Target Population

Locally advanced or metastatic HCC; conducted in China

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04194801

Our clinical trials in

EGFR-mutated non-small cell lung cancer (NSCLC)

Trial Phase

Trial Phase 1/2

Target Population

Target Population

Treatment-resistant EGFR-mutated NSCLC

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04862780

Our clinical trials in

Pediatric cancers

Trial Phase

Trial Phase 1/2

Target Population

Target Population

Solid tumors with a KIT or PDGFRA mutation and gliomas with an H3K27M mutation in pediatric patients

Study Status

Not yet recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04773782